Target intelligence / Profile preview

Other snake venom toxins

Molecular classification
Toxin, Enzyme, Protein family
01

Overview

Other snake venom toxins refers to a heterogeneous collection of bioactive proteins and peptides found in snake venoms that are distinct from the major toxin families such as phospholipases A2 (PLA2s), three-finger toxins (3FTxs), and snake venom metalloproteinases (SVMPs). This category includes diverse molecules such as hyaluronidases, which act as spreading factors by degrading the extracellular matrix, and cysteine-rich secretory proteins (CRISPs) that can inhibit various ion channels [1, 2]. Other components include L-amino acid oxidases (LAAOs) that induce oxidative stress and apoptosis, as well as Kunitz-type serine protease inhibitors and nerve growth factors [3]. These toxins contribute significantly to the clinical manifestations of snakebite envenomation, including local tissue necrosis, systemic hemorrhage, and neurotoxicity [4]. While antivenoms are the standard treatment used to neutralize these toxins through antibody binding, some specific toxins within this group are being investigated as potential leads for drug discovery in areas like anticoagulation and pain management [5].

Other names
Snake venom proteinsNon-conventional snake toxinsMinor snake venom componentsSnake venom enzymes
02

Mechanism of action

Antivenoms neutralize these toxins by binding to their epitopes, preventing interaction with host receptors or substrates. Small molecule inhibitors like varespladib or metalloproteinase inhibitors (e.g., marimastat) bind to the catalytic sites of specific enzymatic toxins to block their activity [4, 5].

03

Biological functions

Extracellular matrix degradationApoptosis inductionIon channel modulationHemostasis disruptionTissue degradation
04

Disease associations

Snakebite envenomationHemorrhageLocal tissue necrosisCoagulopathy
05

Safety considerations

Antivenom-induced anaphylaxisSerum sicknessRapid progression of tissue damageVenom resistance to specific antivenoms
06

Interacting drugs

Antivenom (Polyvalent)

4 more in the full profile.

07

Biomarkers

Venom antigen concentrationProthrombin time (PT)Activated partial thromboplastin time (aPTT)Creatine kinase (CK) levels

Beyond the preview

Go deeper on Other snake venom toxins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Other snake venom toxins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call